1. Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer.
- Author
-
O'Donnell PH, Alanee S, Stratton KL, Garcia-Grossman IR, Cao H, Ostrovnaya I, Plimack ER, Manschreck C, Ganshert C, Smith ND, Steinberg GD, Vijai J, Offit K, Stadler WM, and Bajorin DF
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Agents pharmacology, Carcinoma, Transitional Cell genetics, Carcinoma, Transitional Cell pathology, Cisplatin pharmacology, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Staging, Pharmacogenomic Variants, Survival Analysis, Treatment Outcome, Antineoplastic Agents administration & dosage, Carcinoma, Transitional Cell drug therapy, Cisplatin administration & dosage, Germ-Line Mutation, Polymorphism, Single Nucleotide
- Abstract
Background: Level 1 evidence has demonstrated increased overall survival with cisplatin-based neoadjuvant chemotherapy for patients with muscle-invasive urothelial cancer. Usage remains low, however, in part because neoadjuvant chemotherapy will not be effective for every patient. To identify the patients most likely to benefit, we evaluated germline pharmacogenomic markers for association with neoadjuvant chemotherapy sensitivity in 2 large cohorts of patients with urothelial cancer., Patients and Methods: Patients receiving neoadjuvant cisplatin-based chemotherapy for muscle-invasive urothelial cancer were eligible. Nine germline single nucleotide polymorphisms (SNPs) potentially conferring platinum sensitivity were tested for an association with a complete pathologic response to neoadjuvant chemotherapy (pT0) or elimination of muscle-invasive cancer (
- Published
- 2016
- Full Text
- View/download PDF